Stockscreener 앱 받기
5.02
0.20%
0.010
시간 외 거래:
5.01
-0.010
-0.20%
전일 마감가:
$5.01
열려 있는:
$5.01
하루 거래량:
82,632
Relative Volume:
0.52
시가총액:
$45.34M
수익:
$170.00K
순이익/손실:
$-16.59M
주가수익비율:
-2.6265
EPS:
-1.9113
순현금흐름:
$-15.98M
1주 성능:
-0.20%
1개월 성능:
+11.06%
6개월 성능:
+115.45%
1년 성능:
+112.72%
1일 변동 폭
$5.01
$5.04
1주일 범위
$5.01
$5.05
52주 변동 폭
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
5.02 | 45.25M | 170.00K | -16.59M | -15.98M | -1.9113 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Forecast Cut: What is Lisata Therapeutics Incs market positionInflation Watch & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Lisata Therapeutics Hits New 52-Week High of $5.06 - Markets Mojo
Lisata Therapeutics Q2 2025 Earnings Preview - MSN
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com Nigeria
Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - marketscreener.com
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LSTA Stock Price and Chart — NASDAQ:LSTA - TradingView
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Lisata Therapeutics to Be Acquired by Kuva Labs - The Globe and Mail
Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Per Share Plus Potential $1.00 CVR in 2026 Merger Deal - Minichart
Market movers: Hims & Hers, Lisata Therapeutics, Live Nation Entertainment... - Proactive financial news
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Yahoo Finance
Lisata Therapeutics to Be Acquired by Kuva Labs in $5.00-Per-Share Tender Offer Plus $1.00 CVR - TradingView
Kuva Labs to acquire Lisata (Nasdaq: LSTA) for $5.00 cash plus CVR - Stock Titan
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs - Nasdaq
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs in $5.00 per Share Deal - GuruFocus
Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc. - TradingView
Lisata Therapeutics Announces Acquisition by Kuva Labs Inc. with $5.00 Cash Offer per Share - Quiver Quantitative
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - TipRanks
Lisata Extends Kuva Tender Offer Term Sheet to March 7 as Acquisition Talks Continue - TradingView
Will Lisata Therapeutics Inc. stock go up in YEARJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - mfd.ru
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq
LSTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Why is Lisata Therapeutics Inc. stock going downAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
What is the long term forecast for Lisata Therapeutics Inc. stockJuly 2025 Decliners & Comprehensive Market Scan Insights - mfd.ru
Can Lisata Therapeutics Inc. keep up with sector leadersTrade Risk Summary & Free Accurate Trade Setup Notifications - mfd.ru
LSTA PE Ratio & Valuation, Is LSTA Overvalued - Intellectia AI
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Finansavisen
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - stocktitan.net
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):